8-K

0000950170-23-000230.txt : 20230105 0000950170-23-000230.hdr.sgml : 20230105 20230105161248 ACCESSION NUMBER: 0000950170-23-000230 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230104 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 23511428 BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 8-K 1 kalv-20230104.htm 8-K 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 04, 2023

KALVISTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware			001-36830	20-0915291
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)

55 Cambridge Parkway Suite 901E
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 999-0075

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		KALV		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 4, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) announced the appointment of Benjamin L. Palleiko, currently the Company’s Chief Business Officer and Chief Financial Officer, to the position of President of the Company, effective as of January 4, 2023.

Biographical information for Mr. Palleiko may be found in the Company’s definitive proxy statement (“Proxy Statement”) relating to its 2022 Annual Meeting of Stockholders, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 22, 2022.

The Company previously entered into (i) an indemnity agreement and (ii) amended and restated employment agreement with Mr. Palleiko. The forms of the indemnity agreement and amended and restated employment agreement were previously filed with the SEC as Exhibit 10.14 to the Company’s Registration Statement on Form S-1 on December 19, 2014 and Exhibit 10.6 to the Company’s Annual Report on Form 10-K for the year ended April 30, 2019 on July 16, 2019, respectively, and incorporated by reference herein.

There are no arrangements or understandings between Mr. Palleiko and any other persons, pursuant to which he was appointed as President, no family relationships among any of the Company’s directors or executive officers and Mr. Palleiko and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure.

The Company announced the appointment of Mr. Palleiko to the position of President of the Company in a press release furnished as Exhibit 99.1.

The information in Item 7.01 of this Current Report, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, unless it is specifically incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description

99.1		Press release issued by KalVista Pharmaceuticals, Inc. dated January 5, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			KALVISTA PHARMACEUTICALS, INC

Date:	January 5, 2023	By:	/s/ T. Andrew Crockett
			T. Andrew Crockett Chief Executive Officer and Director

EX-99.1 2 kalv-ex99_1.htm EX-99.1 EX-99.1

KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

-

Expanded role to lead business and commercial growth –

-

Follows $58 million financing in December 2022 led by top-tier syndicate –

Cambridge, MA and Salisbury, England, January 5, 2023 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the promotion of Ben Palleiko, the Company’s current Chief Business Officer and Chief Financial Officer, to the additional title of President. In this expanded role, Mr. Palleiko will be responsible for leading broadly the Company’s future business growth, including development of the commercial organization for the intended worldwide launch of sebetralstat, currently in Phase 3 clinical development as the first potential oral, on-demand treatment for hereditary angioedema (HAE) attacks.

“I am excited to take on this larger role as KalVista continues to grow and prepares to become a commercial organization,” said Mr. Palleiko. “With the strong financial position resulting from our recent equity offering, KalVista has the resources to bring the first oral, on-demand therapy to people living with HAE across the world. We believe sebetralstat represents a significant potential advance in the treatment of this disease, and we intend to move aggressively to begin to establish the business operations and other capabilities needed for an eventual worldwide launch.”

Mr. Palleiko’s promotion follows a $58 million registered direct share offering completed in December 2022. The financing was led by TCGX, Venrock Healthcare Capital Partners and Frazier Life Sciences, with additional participation by selected existing investors, and was priced at a 17% premium to the share price on the offering date. The net proceeds from this financing, together with the Company’s existing cash, investments and anticipated receipts as of October 31, 2022, provides access to over $190 million pro forma as of that date to support execution of the ongoing KONFIDENT Phase 3 trial for KalVista’s lead compound sebetralstat, initial preparations by the Company for commercial launch and sales following anticipated FDA approval, and further development of the Company’s Factor XIIa program. The Company anticipates data from KONFIDENT in the second half of 2023, following which it expects to file a New Drug Application in the first half of 2024. With the completed financing, KalVista now expects to be able to fund operations into 2025.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2022, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

KalVista Pharmaceuticals, Inc.

Jarrod Aldom

Vice President, Corporate Communications

(201) 705-0254

jarrod.aldom@kalvista.com

EX-101.LAB 3 kalv-20230104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 4 kalv-20230104.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 kalv-20230104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Jan. 04, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 04, 2023
Entity Registrant Name	KALVISTA PHARMACEUTICALS, INC.
Entity Central Index Key	0001348911
Entity Emerging Growth Company	false
Securities Act File Number	001-36830
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0915291
Entity Address, Address Line One	55 Cambridge Parkway
Entity Address, Address Line Two	Suite 901E
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02142
City Area Code	857
Local Phone Number	999-0075
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	KALV
Security Exchange Name	NASDAQ

XML 7 kalv-20230104_htm.xml IDEA: XBRL DOCUMENT 0001348911 2023-01-04 2023-01-04 0001348911 false 8-K 2023-01-04 KALVISTA PHARMACEUTICALS, INC. DE 001-36830 20-0915291 55 Cambridge Parkway Suite 901E Cambridge MA 02142 857 999-0075 false false false false Common Stock, $0.001 par value per share KALV NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports kalv-20230104.htm kalv-20230104.xsd kalv-20230104_lab.xml kalv-20230104_pre.xml kalv-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kalv-20230104.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "kalv-20230104.htm" ] }, "labelLink": { "local": [ "kalv-20230104_lab.xml" ] }, "presentationLink": { "local": [ "kalv-20230104_pre.xml" ] }, "schema": { "local": [ "kalv-20230104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kalv", "nsuri": "http://www.kalvista.com/20230104", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "kalv-20230104.htm", "contextRef": "C_82aca4b5-da0e-4b21-80ec-f5c4494b08af", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "kalv-20230104.htm", "contextRef": "C_82aca4b5-da0e-4b21-80ec-f5c4494b08af", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.kalvista.com/20230104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-000230-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-000230-xbrl.zip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